ASCEND Study of Natalizumab Efficacy on Disability in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Baseline Demographics and Disease Characteristics

被引：0
|
作者：
Mikol, Daniel
Freedman, Mark S.
Goldman, Myla D.
Hartung, Hans-Peter
Havrdova, Eva
Jeffery, Douglas
Kapoor, Raj
Miller, Aaron
Sellebjerg, Finn
Lee, Sophia
Chen, Yun
Cadavid, Diego
Ticho, Barry
机构：
来源：
ANNALS OF NEUROLOGY | 2013年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [21] Increases in Eomes-expressing Th cells in secondary progressive multiple sclerosis (SPMS) reveal patients at risk of increased disability
    Raveney, B.
    Sato, W.
    Takewaki, D.
    Lin, Y.
    Okamoto, T.
    Araki, M.
    Oki, S.
    Yamamura, T.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 764 - 764
  • [22] Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
    Oreja-Guevara, C.
    Rio, J.
    Ara Callizo, J. R.
    Hernandez Perez, M. A.
    Gracia Gil, J.
    Alonso Torres, A. M.
    Pilo de la Fuente, B.
    Ramio-Torrenta, L.
    Eichau Madueno, S.
    Gascon Gimenez, F.
    Casanova Estruch, B.
    Martinez Yelamos, S.
    Aguado Valcarcel, M.
    Martinez Gines, M.
    El Berdei Montero, Y.
    Lopez Real, A. M.
    Gonzalez Quintanilla, V.
    Lopez de Silanes, C.
    Martinez Rodriguez, J. E.
    Costa-Frossard Franca, L.
    Garces Redondo, M.
    Labiano Fontcuberta, A.
    Castellanos Pinedo, F.
    Garcia Merino, J. A.
    Munoz Fernandez, C.
    Castillo Trivino, T.
    Meca-Lallana, V.
    Pena Martinez, J.
    Rodriguez Antiguedad, A.
    Prieto Gonzalez, J. M.
    Aguera Morales, E.
    Perez Molina, I.
    Solar Sanchez, M.
    Herrera Varo, N.
    Meca-Lallana, J. E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 306 - 307
  • [23] Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Vermersch, P.
    Giovannoni, G.
    Fox, R.
    Rouyrre, N.
    Karlsson, G.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 380 - 381
  • [24] Efficacy of Natalizumab in Multiple Sclerosis Patients with High Disease Activity: A Danish Nationwide Study
    Oturai, Annette Bang
    Koch-Henriksen, Nils
    Petersen, Thor
    Jensen, Poul Erik Hyldgaard
    Sellebjerg, Finn
    Sorensen, Per Soelberg
    NEUROLOGY, 2009, 72 (11) : A315 - A315
  • [25] Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
    Oturai, A. B.
    Koch-Henriksen, N.
    Petersen, T.
    Jensen, P. E. H.
    Sellebjerg, F.
    Sorensen, P. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (03) : 420 - 423
  • [26] Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial
    Sokhi, D. S.
    Hooker, J.
    Williams, M. J.
    Amezcua, L.
    Shamshudin, A.
    Hussein, Y. E.
    Betti, P.
    Amariati, H.
    Karimi, N.
    Gondi, S.
    Pei, J.
    Bulhan, H.
    Okaka, D.
    Acosta, J.
    Saleh, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 841 - 841
  • [27] A potential role for continuation of natalizumab therapy in patients with secondary progressive multiple sclerosis.
    Yap, Siew Mei
    McNicholas, Nuala
    Tubridy, Niall
    Hutchinson, Michael
    McGuigan, Christopher
    NEUROLOGY, 2017, 88
  • [28] Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis
    Miller, David
    Cree, Bruce
    Dalton, Catherine
    Freedman, Mark
    Hartung, Hans
    Kappos, Ludwig
    Lubetzki, Catherine
    Lublin, Fred
    MacManus, David
    Montalban, Xavier
    Weiner, Howard
    Wolinsky, Jerry
    De Vera, Ana
    Kornyeyeva, Elena
    Li, Bingbing
    Pirozzi, Claudia
    von Rosenstiel, Philipp
    Polman, Chris
    NEUROLOGY, 2013, 80
  • [29] The efficacy of copaxone therapy in patients with secondary progressive multiple sclerosis
    Zavalishin, I
    Bejn, B
    Sholomov, I
    Alifirova, V
    Poverennova, I
    Baljazin, V
    Okladnikov, V
    Klushin, D
    Peresedova, A
    Stoida, N
    Zaharova, M
    Adarcheva, L
    Nijazbekova, A
    Askarova, L
    Olejnikov, V
    Rebrova, O
    Durseneva, O
    Kuranova, O
    Orlova, J
    Tel'nova, K
    Goncharova, Z
    Volkova, L
    Turova, E
    Okuneva, I
    Nechaeva, J
    Reikhert, L
    Bychenko, S
    Markina, O
    MULTIPLE SCLEROSIS, 2005, 11 : S84 - S84
  • [30] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
    Benedict, Ralph
    Fox, Robert
    Tomic, Davorka
    Cree, Bruce
    Vermersch, Patrick
    Giovannoni, Gavin
    Bar-Or, Amit
    Gold, Ralf
    Ritter, Shannon
    Karlsson, Goeril
    Wolf, Christian
    Kappos, Ludwig
    NEUROLOGY, 2019, 92 (15)
12345